Subject Index

Abdominal adiposity and insulin resistance, 111–112
Acetyl CoA carboxylase activity in liver, 186
Acipimox
  and cholesterol in liver, 190
  and fish oil, 183–190
Adipocyte glucose transporter, skeletal muscle, and heart, 94
Adipocyte insulin binding and diet, 152–153
Adipocyte insulin resistance, fish oil and lard diet in, 98–100
Adipocyte plasma membrane composition and diet, 151–152
Adipocytes
  glucose transport in, after fish oil, 238–239
  impaired insulin-stimulated glucose uptake in, 92
Aerobic exercise, effects of, 132–133
Aging and B-cell function, 233–235
Alcohol consumption and weight gain, 147
American Diabetes Association dietary recommendations, 199–200
Antihypertensive effect of fish oils, 40–42
Antioxidants, influence of, on blood pressure, 42
Arachidonic acid
  and diet, 326–327
  and streptozotocin diabetes, 365–366
Athrogenesis, lipoproteins and, 360–361
Atherosclerosis, fish oil in, 376–377
Atherosclerotic vascular disease, NIDDM and, 341–342
Australian Aborigines, diet of, 326–327

Behavioral factors in weight gain, 147
Beta-adrenergic receptors, 282, 284, 287
Binding, insulin, and nuclear envelope, 157–159
Blood pressure
  and fish oil in hypertriglyceridemia, 353–355
  and omega-3 fatty acids, 35–42
  glucoregulation, and triglyceridemia, 57–67
  influence of antioxidants on, 42
  low salt diet and, 289–294
Body composition
  and fuel oxidation, 127
  and weight maintenance, 129–132
Body weight
  food consumption and, 185–186
  gain, risk factors for, 143–144
  maintenance, 136
  regulation, 122

Calorimeter, indirect, 142
Carbohydrate conversion into fat, 124
Carbohydrate oxidation, 126
Carbohydrate-to-fat ratios, 136
Carbohydrates
  dietary, effects of, 57–67
  dietary fats, and weight, 122–137
Cardiovascular disease
  and diabetes, 112–113
  and insulin action, 110–111
  obesity and diabetes in, 344
Cardiovascular risk, diet and, 192
Catecholamines in hypertriglyceridemia, 283, 284, 287
Cell cultures and lipid modification, 164–166
Cerebrovascular disease in Greenland and Denmark, 9
Chinese hamster ovary cell line and LDL binding, 178–179
Cholesterol blood levels and high fat diet, 100
Chylomicronemia reduced by fish oil, 23
Corticosterone, 134
Cynomologus monkeys and lipid levels, 180

Deadly quartet. *See* Insulin resistance syndrome
Denmark and Greenland, mortality patterns in, 9
DHA. *See* Docosahexaenoic acid
Diabetes
  abnormal serum fatty acid composition and, 367–370
  adult-onset, and fish oil, 337–340
  and cardiovascular disease, 325
  and dietary fatty acids, 159
  dietary n-3 fatty acids in, 244–248
  docosahexaenoic acid emulsion in, 207–211
  erythrocyte and platelet fluidity in, 371–372
  fatty acids and hypertension in, 331–333
  fish oil, and insulin action in fat cells, 213
  fish oil in, 341–342
  fish oils and insulin action in, 250–257
  hypertriglyceridemia in patients with, 85
  in Eskimos, 9–10
  insulin action in, 258–268
  insulin resistance and, 193
  metabolic effects of n-3 fatty acids in, 272–278
  monounsaturated fatty acids and, 199–205
  non-insulin dependent, in San Luis Valley, 46–56

postprandial triglycerides after lipid load in, 315–320
n-6/n-3 ratio in, 258–268
streptozotocin
and archidonic acid, 365–366
muscle protein levels in, 218–225
type 2, and omega-3 fatty acids, 114
with hypertriglyceridemia, 300
Diabetic adipocytes and glucose transport, 153–155
Diet
and insulin responsiveness, 151–162
and nuclear envelope, 157–159
diabetes and, 199–205
fat-modified, glucose and lipid metabolism in, 279–280
fat-modified *vs* low fat, 192–196
n-3 fatty acids in, 69–79
and diabetes, 244–248
high carbohydrate *vs* high fat, 102
high fat
and body weight and adipose tissue weight, 99
in insulin resistance, 84
in streptozotocin-treated rats, 228-236
high sucrose, glucose transport in adipocytes on, 237–243
insulin resistance induced by, 82–88
low salt, in hypertriglyceridemia, 289–294
Dietary recommendations in diabetes, 343–345
Docosahexaenoic acid emulsion in diabetes, 207–211
Dyslipidemia
and increased insulin concentrations, 1–7
in Asian Indians, 265–266
mechanisms of, 6

Energy expenditure, components of, 142–143
Energy intake *vs* energy expenditure, 141
Environmental factors and insulin responsiveness, 168
Epidemiologic observations on diet, 114
Epidemiologic studies on Eskimos and fish intake, 9–14
Erythrocyte membrane fluidity, fatty acids and, 371–372
Eskimos
cardiovascular disease in, 9–10
diabetes in, 9–10
diet of, 10
epidemiologic studies on, and fish intake, 9–14
hemorrhagic stroke in, 11
plasma lipids in, 9–10
Exercise, effects of, 132

Familial disorder, obesity as, 141–142
Fat
and diabetes, 259–261
carbohydrates, and weight, 122–137
dietary impact of, 132
fish, and blood pressure, 35–42
oxidation of, 124, 145
subtypes, and insulin action, 107
Fat balance *vs* energy balance, 148
Fat cells, insluin action in, with fish oil, 213–216
Fat-modified *vs* low fat diets, metabolic effects of, 192–196
Fatty acid changes in triglyceride and glucose, 351–352
Fatty acid composition of membrane phospholipids, 86
Fatty acid oxidation, inhibition of, in perfused liver, 357–359
Fatty acid synthetase and high fat diet, 99, 100
Fatty acid utilization in muscle after fructose feeding, 60
Fatty acids. *See also* Omega-3 fatty acids
and hypertension in diabetes, 331–333
and insulin resistance, 69–79
and LDL binding, 178–181
erythrocyte and platelet fluidity effects in, 371
from fish oil, 16–34
high, glucose tolerance and, 279–280
hypolipidemia and, 378–379
in diabetes, 272–278
in dietary treatment of metabolic disorders, 322–327
insulin, and sucrose, 346–348
insulin resistance and, 84
insulin response to, in diabetes, 245
kinetics of, in hypertriglyceridemia, 373–375
monounsaturated, in diabetes, 199
serum, and NIDDM, 367–370
Fiber, vegetable, in diet, 194
Fish
consumption in Eskimo diet, 10
dietary fats, and blood pressure, 35–42
intake
and coronary heart disease, 10–11
and Eskimos, epidemiologic studies on, 9–14
low, biologic effects of, 13
Fish oil
and acipimox, 183–190
and atherosclerosis, 376–377
and blood pressure, 353–355
and cardiovascular risk in NIDDM, 113–114

and cholesterol, 189
and glucose tolerance, 114
and hypertension, 37
and insulin in diabetes, 110–118, 250–257
and insulin resistance, 91–92
and lard diet in obesity, 98–100, 349–350
and LDL binding, 180–181
and serum lipids, 113–114
anticoronary action of, 16–32
dietary, and insulin action, 110–118
fatty acids from, 16–34
glucose uptake in adipocytes and, 237–243
glycemic control and, 114
hypolipidemic effects of, 378–379
hypotriglyceridemia, and diabetes, 337–340
in NIDDM, 341–342
in streptozotocin-induced diabetes, 218–225
insulin action in fat cells and, 213–216
Food intake regulation and energy expenditure, 127
Food quotient (FQ), 123
Food, thermic effect of, 142
FQ. *See* Food quotient
Frequent sampling intravenous glucose tolerance test (FSIGT), 296, 374
Fructose feeding and insulin action, 58
FSIGT. *See* Frequent sampling intravenous glucose tolerance test
Fuel oxidation and body composition, 127

Glibenclamide in diabetes, 266
Glucocorticoid hormones and obesity, 134
Glucoregulation, triglyceridemia, and blood pressure, 57–67
Glucose
and insulin stimulation in obese subjects, 173, 174
n-3 fatty acids and, 252
high fat diet and, 100
in diabetes, 337–340
in hypertriglyceridemia, 295–300
Glucose metabolism
and NIDDM, 193
in fat-modified diet, 279–280
in hypertriglyceridemia, 351–352
Glucose regulation after high fructose intake, 58
Glucose, serum, and insulin in diabetes, 207–211
Glucose tolerance
and dietary lipids, 46–56
and fish oil, 114, 378–379
and insulin, 92, 112–113
in streptozotocin-treated rats, 228–236
Glucose tolerance test to assess insulin action, 106
Glucose transport
and insulin action in adipocytes, 153–155
in adipocytes after fish oil, 238–239
in streptozotocin-induced diabetes, 218–225
Glucose transporter
and diet, 94, 99, 100
insulin stimulation and, 91–92
protein levels in diabetes, 218–225
Glucose uptake and insulin resistance, 111
Glucose utilization, fish oil and, 214
GLUT. *See* Glucose transporter
Glycemic control and omega-3 fatty acids, 116
Glycogen reserves, 124
Glycogen, tissue, and triglyceride stores, 93
Greenland and Denmark, mortality patterns in, 9

High density lipoproteins (HDL) and insulin, 5
Heart, skeletal muscle, and adipocyte glucose transporter, 94
Hemorrhagic stroke in Eskimos, 11
Hereditary hypertriglyceridemia
low salt diet in, 289–294
nonobese rat model of, 61
High carbohydrate *vs* high fat diets, 102
Hispanics, diabetes among, 46–56
HTG. *See* Hypertriglyceridemia
Hyperlipemia
and obesity, diet in, 349–350
fish oil and high lard diet in, 98–100
Hypertension and fatty acids in diabetes, 331–333
Hypertriglyceridemia, 111
blood pressure and fish oil, 353–355
fatty acid changes in, 351–352
fish oil and, 16–34
insulin action in, 295–300
insulin resistance in, 281–287
kinetics of free fatty acids in, 373–375
low salt diet in, 289–294
Hypolipidemic effect of fish oil, 183–190
Hypotriglyceridemia, fish oil, and diabetes, 337–340

IDDM. *See* Diabetes
Indian (Asian) diet, 261–263
Insulin
concentrations and serum glucose in diabetes, 207–211
effect on glucose transport in adipocytes, 240–241, 242
fatty acids, and sucrose, 346–348

glucose tolerance and, in fat-modified diet, 279–280
Insulin action
after high fructose intake, 59
after high sucrose intake, 59
and high-fat diet, 100
and 24-hour glycemia, 344
and lipoprotein concentrations, 1–3
and VLDL, 4
dietary fish oil and, 110–118, 213–216, 250–257
dietary lipids and, 102–108
fatty acids, and hypertriglyceridemia, 351
glucose tolerance and, 112–113
impaired, and fatty acid flux, 111
and free fatty acids, 5
and HDL, 5
and VLDL, 5
lipid oxidation and, 254–256
omega-3 fatty acids and, 116
Insulin binding
adipocyte, and diet, 152–153
and altered lipid composition of cells, 165
in adipocytes and diet, 152
in spontaneously diabetic rat, 159–160
Insulin receptor signaling and lipid environment, 167
Insulin receptor tyrosine kinase activity, 164–170
Insulin resistance
after high fat-fed rats, 91–96
and lipoprotein abnormalities, 6
and secretion in hypertriglyceridemia, 295–300
and starvation, 168
early study by Himsworth, 106
fish oil and high lard diet in, 98–100
high fat diet-induced, 82–88
in hypertriglyceridemic rats, 281–287
sucrose-induced, 69–79
types of, 373–375
Insulin resistance syndrome, etiology of, 1
Insulin response
after neonatal streptozotocin in rats, 232–235
in muscle, 155–157
to fish oil in diabetes, 277
to n-3 fatty acids in diabetes, 244–245
Insulin secretion
and dietary lipids, 172–177
and fish oil, 378–379
Insulin sensitivity
and glucose tolerance, 92
and weight gain, 146
dietary fiber and, 195
Insulin-dependent diabetes, monounsaturated fat diet in, 203
Ischemic heart disease in Greenland and Denmark, 9

Lard and fish oil diet in obesity, 98–100, 349–350
LDL and insulin, 4–5
LDL binding and dietary fatty acids, 178–181
LDL receptor and cholesterol in liver, 188
Linoleic acid and insulin binding, 166
Lipid load, oral, triglycerides and lipoproteins after, 315–320
Lipid modulation of tyrosine kinase activity, 164–170
Lipids
and glucose tolerance, 46–56
basal and prandial, in NIDDM, 344
dietary, and insulin action, 102–108, 151–162
and insulin secretion, 172–177
in Eskimos, 9–10
structural order parameters of, 173–174, 175
Lipogenesis, 124
Lipoproteins
concentrations and insulin, 1–3
effects of fish oil on, 16–34
diabetes after lipid load, 315–320
lipase and insulin resistance, 111
oxidation of, 363–364
Liver
glycogen concentrations and diet, 93
inhibition of fatty acid oxidation in, 357–359
malic enzyme activity, and triiodothyronine, 360–361
Low salt diet in hypertriglyceridemia, 289–294

Malic enzyme activity and triiodothyronine, 360–361
Membrane composition
and diet, 152
and fluidity, 94–96
Membrane lipids
and insulin action, 91
and insulin receptor signaling, 167
3-Mercaptopropionic acid to inhibit fatty acid oxidation, 357–359
Metabolic effects
of high fat diets, 100
of insulin resistance, 111
of omega-3 fatty acids, 116
Metabolic rate and obesity, 144
Metabolic syndrome and triglycerides, 302–311
Metabolism, abnormal, and diet, 195
Middle age

diet and glucose tolerance in, 12
hypertriglyceridemia in, 295–300
Minimal Model to assess insulin action, 106
Monounsaturated fatty acids
in diabetes, 201
sources of, 204
Multiple Risk Factor Intervention Trial, 11
Muscle
GLUT 4 protein levels in diabetes, 218–225
insulin responsiveness in, 155–157
skeletal, heart, and adipocyte glucose transporter, 94
skeletal, insulin action on, 85

N-3 fatty acids
from fish oil, 16–32
in diabetes, 244–248, 272–278
in Eskimo diet, 10
long-term effects of, 13
N-6 and n-3 fatty acids in metabolic disorders, 322–327
N-6/n-3 ratio for insulin action in diabetes, 258–268
NIDDM (Non-insulin-dependent diabetes mellitus). *See also* Diabetes
and insulin resistance, 112–113
etiology of, 86
genetic predisposition in, 86, 88
lifestyle factors in, 86, 88
Nitrogen balance and body weight, 123
Nuclear envelope and diet, 157–159
Nutrient intake and oxidation in obesity, 145
Nutritional states, altered, and lipid modulation, 167

Obesity
and diabetes, 344
and insulin resistance, 108
fish oil and high lard diet in, 98–100, 349–350
glycemia and insulin secretion in, 172–177
pathogenesis of, 144
risk factors for, 141–148
treatment of, 148
Omega-3 fatty acids
and blood pressure, 35–42
and insulin action, 116
and insulin secretion, 118
and muscle synthesis, 155–156
blood pressure lowering effect of, 37–42
effects on glycemic control, 114
in fat, 151–152
in insulin resistance, 84
in membrane phospholipid, 86
Omega-6 fatty acids in insulin resistance, 84
Oxidative modification of low density lipoproteins, 360–361

Physical activity, 142–143
and weight gain, 144
Pima Indians studies, 144
Plasma lipids in Eskimos, 9–10
Plasma lipoproteins and insulin resistance, 3–4
Platelet aggregation, reduced, in Eskimos, 10
Population studies
diet and blood pressure in, 35–36
insulin and lipoproteins in, 2
Postprandial response
to lipid load in diabetes, 315–320
in healthy subjects, 302–311
Prostaglandin $F_{2\alpha}$ and E_2 synthesis, 155
Protein levels of GLUT 4 in diabetes, 218–225
Protein reconstitution and protein-lipid interactions, 166–167
PUFA. *See* Fatty acids

Rabbits, atherosclerosis in, and fish oil, 376–377
Rats
hereditary herpertriglyceridemic, 351–352
fish oil in, 353–355
low salt diet in, 289–294
insulin resistance after high fat diet in, 91–96
spontaneously diabetic, insulin binding in, 159–160
streptozotocin-treated, high fat feeding in, 232–235
Zucker, obesity and hyperlipemia in, 349–350
Respiratory quotient (RQ), 123
RQ. *See* Respiratory quotient

San Luis Valley Diabetes Study, 46–56
insulin and lipoproteins in, 3
risk factors in, 47–48
Saturated fats
and insulin resistance, 92
ω-6 monounsaturates, and *trans* fatty acids, 36
Serum cholesterol and LDL receptor in liver, 186–187
Serum glucose
and impaired insulin action, 185–186
and insulin response in diabetes, 244–248
Serum lipids and fish oil, 113–114
Seven Countries Study of cardiovascular disease, 11

Skeletal muscle, heart, and adipocyte glucose transporter, 94
Socioeconomic factors in weight gain, 147
Sodium intake, dietary, and response to fish oils, 39–40
Starvation and insulin resistance, 168
Streptozotocin diabetes
  and arachidonic acid feeding, 365–366
  DHA emulsions in, 207–208
  fish oil effects in, 213
  muscle GLUT 4 protein levels in, 218
Streptozotocin-treated rats, glucose tolerance in, 228–236
STZ. *See* Streptozotocin
Sucrose
  and acipimox effects on body weight, 185–186
  and glucose tolerance, 58
  and insulin resistance, 69–79, 168
  insulin, and fatty acids, 346–348
Syndrome X. *See* Insulin resistance syndrome
Syndromes of insulin resistance, 86

Tissue glycogen and triglyceride stores, 93
Triglyceridemia, glucoregulation, and blood pressure, 57–67
Triglycerides
  accumulation in liver, 357–359
  and acetyl CoA carboxylase, 188
  and insulin, 4
  and metabolic syndrome, 302–311
  and sucrose diet, 186
  high, and skeletal muscle insulin action, 85
  high fat diet, 100
  metabolism in streptozotocin diabetes, 218–225
  postprandial, and lipids in diabetes, 315–320
  serum, in Wistar rat, 62
  synthesis and n-3 fatty acids, 28–30
Triiodothyronine and malic enzyme activity, 360–361
Type 1 diabetes, fatty acids and hypertension in, 331–333
Tyrosine kinase activity
  and insulin action, 166
  in liver, and sucrose, 346–348

VLDL and insulin, 4

Weight, dietary fats, and carbohydrates, 122–137
Weight gain, socioeconomic factors in, 147
Western Electric Study of diet, 11

Zucker rats, obesity and hyperlipemia in, 349–350
Zutphen Study of Dutch diet, 11

Index of Contributors

Alamowitch, C., 213–217
Ausieker, S., 315–321

Bakker, I. M., 228–236
Baracos, V. E., 151–163
Baše, J., 272–278
Baur, L. A., 82–90
Beilin, L. J., 35–45
Beyer, J., 302–314, 315–321
Biesalski, H. K., 302–314
Bílá, V., 57–68
Bogardus, C., 141–150
Bohov, P., 346–348, 360–362, 367–370
Boillot, A., 213–217
Brtko, J., 360–362
Bruzzo, F., 213–217

Carlotti, M., 98–101, 349–350
Cattaneo, A. G., 172–177
Caviezel, F., 172–177
Cheema, S., 151–163
Chevalier, A., 213–217
Clandinin, M. T., 151–163
Collier, F. McL., 365–366
Collier, G. R., 322–330, 365–366
Connor, S. L., 16–34
Connor, W. E., 16–34, 337–340
Crémel, G., 164–171, 346–348
Cerný, L., 351–352

DeFrancesco, C. A., 16–34
Dobešová, Z., 57–68, 281–288
Dvořák, P., 295–301, 373–375

Edelsteinová, S., 353–356

Fenselau, S., 302–314, 315–321
Ferretti, G., 371–372
Feskens, E. J. M., 9–15
Ficková, M., 164–171, 237–243, 346–348
Field, C. J., 151–163
Flatt, J. P., 122–140
Földeš, O., 289–294
Fontvieille, A. M., 141–150
Fryer, L. G., 91–97
Fumelli, P., 371–372

Galassi, R., 371–372
Garg, A., 199–206
Gelienová, K., 367–370
Giansanti, R., 371–372
Gmeiner, B., 363–364
Guichard, C., 98–101, 349–350

Hainault, I., 98–101, 349–350
Hajduch, E., 98–101, 349–350
Hamazaki, T., 207–212
Hamman, R. F., 46–56
Hannah, J., 178–182
Hatcher, L., 337–340
Heine, R. J., 110–121
Hermann, M., 183–191, 363–364
Howard, B. V., xiii, 1–8, 178–182, 343–345
Howard, W. J., 341–342
Hromadová, M., 183–191, 360–362
Hubert, P., 164–171, 346–348
Hušek, P., 281–288

Ježová, D., 289–294

Karhapää, P., 279–289
Kasim, S. E., 250–257
Kataoka, S., 178–182
Kaul, S., 178–182
Kazdová, L., 57–68, 69–81, 272–278, 376–377
Keppler, I., 302–314
Klimeš, I., xi, 57–68, 69–81, 164–171, 183–191, 218–227, 237–243, 289–294, 343–345, 346–348, 353–356, 360–362, 367–370
Knopp, J., 360–362
Kobayashi, M., 207–212
Kohout, M., 272–278
Kovácsová, B., 353–356
Křen, V., 57–68
Kriketos, A. D., 82–90
Kristek, F., 353–356
Kromhout, D., 9–15
Kruszynska, Y. T., 91–97
Kuneš, J., 57–68, 281–288
Kvapil, M., 295–301, 373–375
Kyselovič, J., 353–356

Laakso, M., 279–280
Landgraf, R., 331–336
Langer, P., 360–362
Laue, C., 302–314
Lavau, M., 98–101, 349–350
Leray, C., 164–171
Leray, V., 164–171
Lichardus, B., 289–294
Luo, J., 213–217

Macho, L., 237–243, 346–348
Mäkimattila, S., 279–280
Mäkinen, E., 279–280
Marshall, J. A., 46–56

Matějčková, M., 376–377
Mazzanti, L., 371–372
Meuillet, E., 164–171
Minchenko, A., 183–191
Mitková, A., 183–191, 218–227, 237–243, 289–294, 353–356
Moss, R., 218–227

Nakamura, N., 207–212
Nakamura, Y., 357–359
Nedvídek, J., 281–288
Nedvídková, J., 281–288
Novakova, V., 376–377

Opltová, H., 281–288

Pan, D. A., 82–90
Parillo, M., 192–198
Pelikánová, T., 272–278
Phatak, R. B., 258–271
Písaříková, A., 378–379
Prellwitz, W., 302–314, 315–321
Prince, M. J., 337–340
Probst, R., 302–314, 315–321

Rabini, R. A., 371–372
Radder, J. K., 228–236
Raheja, B. S., 258–271
Rao, M. B., 258–271
Räsänen, M., 279–289
Ravussin, E., 141–150
Riccardi, G., 192–198
Riddle, M., 337–340
Rizkalla, S. W., 213–217
Roques, M., 164–171

Sadikot, S. M., 258–271
Schectman, G., 178–182
Schrezenmeir, J., 302–314, 315–321
Schwab, U., 279–280
Šeböková, E., 69–81, 183–191, 218–227, 237–243, 289–294, 343–345, 353–356, 360–362, 367–370
Sinclair, A. J., 322–330
Šindelková, E., 378–379
Slama, G., 213–217
Smith, F. E., 337–340
Staedel, C., 164–171, 346–348
Štolba, P., 57–68, 218–227, 281–288, 295–301, 373–375
Storlien, L. H., xii, 82–90, 343–345
Švaboová, E., 346–348
Švec, P., 353–356
Swinburn, B. A., 102–109, 141–150

Takazono, I., 357–359
Tutterova, M., 351–352
Tvrzicka, E., 378–379

Ullmann, D., 337–340
Urbanova, D., 376–377
Uusitupa, M., 279–280

Válek, J., 272–278
Vavřinková, H., 351–352
Vessby, B., 244–249
Vidláková, M., 376–377
Vrána, A., 57–68, 69–81, 281–288, 289–294, 351–352, 353–356, 376–377, 378–379

Weber, P., 302–314, 315–321
Wichterle, D., 295–301, 373–375
Wiersma, M. M. L., 218–227, 228–236
Wilson, D., 337–340

Yamamoto, I., 357–359
Yamamoto, M., 357–359
Yamane, K., 178–182

Žák, A., 378–379
Zeman, M., 378–379
Zemánková, A., 289–294
Zuchhold, H. D., 302–314, 315–321